NASDAQ · PRQR
ProQR Therapeutics N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PRQR: Nov 5, 2026
ProQR Therapeutics N.V. Ordinary Shares is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.11. The reported EPS for the same quarter last year was $-0.12.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.11 | $-0.10 | $-0.13 | 4 |
| Dec 2026 | $-0.14 | $-0.10 | $-0.18 | 3 |
| Mar 2027 | $-0.16 | $-0.16 | $-0.16 | 1 |
| Jun 2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · MarketBeat · RTTNews · Zacks- Fintel · Oct 28, 1:59 PM EDTProQR Therapeutics N.V. to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesProQR Therapeutics N.V. announced upcoming presentations highlighting clinical and preclinical progress with AX-0810 and AX-0811 and the broader Axiomer RNA editing platform at TIDES Europe, The Liver Meeting 2026, and Nature Conferences RNA at the Bench and Bedside V. Gerard Pla
- MarketBeat · Oct 2, 4:02 AM EDTProQR Reports First Human Validation of RNA Editing Platform in Liver DiseaseProQR Therapeutics (NASDAQ:PRQR) said its first-in-human data for AX-0810 provided dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is developing NTCP programs for cholestatic liver diseases, in
- RTTNews · Aug 20, 1:15 PM EDTProQR Establishes First Clinical Validation Of Axiomer Platform; AX-0811 Data Due By Year-End(RTTNews) – ProQR Therapeutics N.V. (PRQR), a clinical-stage RNA editing company, recently reported second-quarter 2026 operating and financial results, highlighting the first clinical validation of its proprietary Axiomer RNA editing platform and a strengthened cash position sup
- Zacks · Aug 14, 8:25 AM EDTOutlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue EstimatesOutlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 26, 4:52 AM EDTProQR Prices Direct Offering And Private Placement For $59 Mln In Gross Proceeds; Stock Falls 20%(RTTNews) – ProQR Therapeutics N.V. (PRQR), a clinical-stage biotechnology company, announced on Thursday an underwritten direct offering and private placement.
- RTTNews · Jun 25, 6:55 AM EDTProQR Therapeutics Announces Positive Target Engagement Data From Ongoing Phase 1 AX-0810 Study(RTTNews) – Thursday, ProQR Therapeutics N.V. (PRQR) announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, an investigational Axiomer RNA editing oligonucleotide which aims to reduce toxic bile acid accumulation in the liver.
- Zacks · May 13, 8:15 AM EDTKamada (KMDA) Misses Q1 Earnings and Revenue EstimatesKamada (KMDA) delivered earnings and revenue surprises of -40.02% and -2.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 10:00 AM EDTEarnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Apr 30, 5:30 PM EDTSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue EstimatesSyndax (SNDX) delivered earnings and revenue surprises of +17.95% and -7.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Apr 8, 8:51 AM EDTProQR Forms AI Advisory Board, Partners With Ginkgo To Advance RNA Editing(RTTNews) – ProQR Therapeutics N.V. (PRQR), a company developing RNA editing therapies through its Axiomer platform, has unveiled a new AI-driven strategy that includes a partnership with Ginkgo Bioworks and the formation of an AI Advisory Board.
- Zacks · Mar 12, 10:15 AM EDTProQR (PRQR) Reports Q4 Loss, Lags Revenue EstimatesProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 11, 8:15 AM EDTKamada (KMDA) Q4 Earnings and Revenues Miss EstimatesKamada (KMDA) delivered earnings and revenue surprises of -30.80% and -2.29%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for ProQR Therapeutics N.V. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.